Portage Biotech Inc Stock OTC Bulletin Board

Portage Biotech Inc. develops pharmaceutical and biotech products through to clinical proof of concept focusing on unmet clinical needs. After proof of concept, the Company will look to sell or license the products to various pharmaceutical companies for further development through to commercialization. The Company's research and development work is primarily carried out through approximately two subsidiaries, including Portage Pharmaceuticals Ltd (PPL) and Biohaven Pharmaceutical Holding Company Limited (Biohaven). The Company also holds interests in Sentien Biotechnologies Inc., a regenerative medicine company. PPL focuses on discovering and developing cell permeable peptide (CPP) therapies to normalize gene expression, restore function and improve medical outcomes. Biohaven is engaged in the identification and development of glutamatergic agents for treatment-resistant neuropsychiatric disorders. Its product pipeline includes PPL-003, BHV-0223 and BHV-4157.